多器官代谢谱[18F]F-FDG PET/CT预测可切除非小细胞肺癌新辅助免疫化疗病理缓解
回顾性纳入2020年4月至2024年4月在湘雅医院接受新辅助免疫化疗前基线[18F]F-FDG PET/CT的可切除非小细胞肺癌患者115例,随机分为训练集(70%)和验证集(30%)。基于深度学习自动分割量化原发肿瘤及九个关键器官的代谢参数及其与肝脏比值,构建多器官代谢列线图预测主要病理缓解,训练集与验证集AUC均为0.78。
要点
- 多器官代谢列线图预测主要病理缓解,训练集AUC=0.78(95%CI 0.67-0.88),验证集AUC=0.78(95%CI 0.62-0.94)。
- 验证集中多器官模型较仅肿瘤参数模型特异度更高(100% vs 92%)、阳性预测值更高(100% vs 90%),总体准确率维持76%。
- 五个预测主要病理缓解的代谢参数为脾脏SUVmean、结肠SUVpeak、脊柱TLG、病灶TLG及脾脏与肝脏SUVmax比值。
核心结论
- 首次报道的多器官代谢列线图可无创预测接受新辅助免疫化疗的可切除非小细胞肺癌患者的主要病理缓解,优于传统以肿瘤为中心的方法。
- 该工具通过量化宿主-肿瘤系统性代谢交互,可能有助于指导个体化治疗决策并降低治疗相关风险,代表向精准免疫肿瘤管理模式的转变。
研究设计与样本
- 回顾性队列研究,纳入2020年4月至2024年4月在湘雅医院接受新辅助免疫化疗前基线[18F]F-FDG PET/CT的可切除非小细胞肺癌患者。
- 患者随机分为训练集(70%)和验证集(30%),共115例,主要病理缓解率为63.5%(n=73)。
- 采用基于深度学习的自动分割量化原发肿瘤及九个关键器官的代谢参数(SUVmean、SUVmax、SUVpeak、MTV、TLG)及其与肝脏代谢参数的比值。
- 特征选择采用单因素分析、LASSO回归和随机森林优化三部分方法,最终多变量模型转化为临床可解释的列线图。
- 验证评估区分度、校准度和临床实用性。
主要发现
- 五个代谢参数为预测主要病理缓解的生物标志物:脾脏SUVmean、结肠SUVpeak、脊柱TLG、病灶TLG及脾脏与肝脏SUVmax比值。
- 列线图在训练集AUC=0.78(95%CI 0.67-0.88),验证集AUC=0.78(95%CI 0.62-0.94),校准稳健,决策曲线分析显示临床净获益增强。
- 验证集中多器官模型较仅肿瘤参数模型特异度更高(100% vs 92%)、阳性预测值更高(100% vs 90%),总体准确率维持76%。
关键数值与推荐
- 主要病理缓解率63.5%(n=73/115)。
- 训练集AUC=0.78(95%CI 0.67-0.88),验证集AUC=0.78(95%CI 0.62-0.94)。
- 验证集中多器官模型特异度100% vs 仅肿瘤参数模型92%,阳性预测值100% vs 90%,总体准确率76%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To develop and validate a novel nomogram combining multi-organ PET metabolic metrics for major pathological response (MPR) prediction in resectable non-small cell lung cancer (rNSCLC) patients receiving neoadjuvant immunochemotherapy. METHODS: This retrospective cohort included rNSCLC patients who underwent baseline [18F]F-FDG PET/CT prior to neoadjuvant immunochemotherapy at Xiangya Hospital from April 2020 to April 2024. Patients were randomly stratified into training (70%) and validation (30%) cohorts. Using deep learning-based automated segmentation, we quantified metabolic parameters (SUVmean, SUVmax, SUVpeak, MTV, TLG) and their ratio to liver metabolic parameters for primary tumors and nine key organs. Feature selection employed a tripartite approach: univariate analysis, LASSO regression, and random forest optimization. The final multivariable model was translated into a clinically interpretable nomogram, with validation assessing discrimination, calibration, and clinical utility. RESULTS: Among 115 patients (MPR rate: 63.5%, n = 73), five metabolic parameters emerged as predictive biomarkers for MPR: Spleen_SUVmean, Colon_SUVpeak, Spine_TLG, Lesion_TLG, and Spleen-to-Liver SUVmax ratio. The nomogram demonstrated consistent performance across cohorts (training AUC = 0.78 [95%CI 0.67-0.88]; validation AUC = 0.78 [95%CI 0.62-0.94]), with robust calibration and enhanced clinical net benefit on decision curve analysis. Compared to tumor-only parameters, the multi-organ model showed higher specificity (100% vs. 92%) and positive predictive value (100% vs. 90%) in the validation set, maintaining 76% overall accuracy. CONCLUSIONS: This first-reported multi-organ metabolic nomogram noninvasively predicts MPR in rNSCLC patients receiving neoadjuvant immunochemotherapy, outperforming conventional tumor-centric approaches. By quantifying systemic host-tumor metabolic crosstalk, this tool could help guide personalized therapeutic decisions while mitigating treatment-related risks, representing a paradigm shift towards precision immuno-oncology management.
引用
- Ma Q, Yang J, Guo X, et al. Multi-Organ metabolic profiling with [18F]F-FDG PET/CT predicts pathological response to neoadjuvant immunochemotherapy in resectable NSCLC. Eur J Nucl Med Mol Imaging. 2025. PMID: 40451983. doi:10.1007/s00259-025-07350-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。